EpiPro, a Novel, Synthetic, Activity-Regulated Promoter That Targets Hyperactive Neurons in Epilepsy for Gene Therapy Applications.
Saved in:
| Title: | EpiPro, a Novel, Synthetic, Activity-Regulated Promoter That Targets Hyperactive Neurons in Epilepsy for Gene Therapy Applications. |
|---|---|
| Authors: | Burke CT; Department of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA., Vitko I; Department of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA., Straub J; Department of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA., Nylund EO; Department of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA., Gawda A; Department of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA., Blair K; Department of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA., Sullivan KA; Computational and Predictive Biology, Oak Ridge National Laboratory, Oak Ridge, TN 37830, USA., Ergun L; Department of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA., Ottolini M; Department of Anesthesiology, University of Virginia, Charlottesville, VA 22908, USA., Patel MK; Department of Anesthesiology, University of Virginia, Charlottesville, VA 22908, USA.; UVA Brain Institute, University of Virginia, Charlottesville, VA 22908, USA., Perez-Reyes E; Department of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA.; UVA Brain Institute, University of Virginia, Charlottesville, VA 22908, USA. |
| Source: | International journal of molecular sciences [Int J Mol Sci] 2023 Sep 23; Vol. 24 (19). Date of Electronic Publication: 2023 Sep 23. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
